IRON (Disc Medicine) Total Stockholders Equity : $443.59 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Disc Medicine Total Stockholders Equity?

Disc Medicine's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $443.59 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Disc Medicine's Book Value per Share for the quarter that ended in Dec. 2024 was $14.85. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Disc Medicine's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.07.

Disc Medicine Total Stockholders Equity Historical Data

The historical data trend for Disc Medicine's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Disc Medicine Total Stockholders Equity Chart

Disc Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

-21.86

-64.20

176.60

345.12

443.59

Disc Medicine Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															345.12	338.07	488.83	467.96	443.59

Disc Medicine (NAS:IRON) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Disc Medicine's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(443.587	-	0)	/	29.865
	=	14.85

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Disc Medicine's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.13	+	29.87)	/	443.587
	=	0.07

Disc Medicine Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Disc Medicine's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Disc Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Disc Medicine Inc (NAS:IRON) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Arsenal Street, Suite 101, Watertown, MA, USA, 02472

Website

https://www.discmedicine.com

Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.

Executives

Rahul Khara	officer: General Counsel	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
John D Quisel	director, officer: Chief Executive Officer	128 SIDNEY STREET, CAMBRIDGE MA 02139
William Richard White	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
William Jacob Savage	officer: Chief Medical Officer	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kevin Bitterman	director	C/O POLARIS VENTURE PARTNERS, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451
Mona Ashiya	director, 10 percent owner	C/O SIERRA ONCOLOGY, INC., 2150 - 885 WEST GEORGIA STREET, VANCOUVER, BRITISH COLUMBIA Z4 V6C 3E8
Atlas Venture Fund X, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Joanne Bryce	officer: Chief Financial Officer	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Brian Richard Macdonald	officer: Chief Innovation Officer	C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Ai Dmi Llc	10 percent owner	C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Atlas Venture Associates Opportunity I, Llc	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Access Industries Holdings Llc	10 percent owner	C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019